LOC285232: A Pseudogene for PRPAT, A Potential Drug Target Or Biomarker
LOC285232: A Pseudogene for PRPAT, A Potential Drug Target Or Biomarker
Unlocking the Potential of LOC285232: A Phosphoribosyl Pyrophosphate Amidotransferase Pseudogene as a Drug Target or Biomarker
Phosphoribosyl pyrophosphate amidotransferase (PRPAT) is a key enzyme in the pyruvate pathway, a critical metabolic pathway for cellular energy metabolism. The dysfunction of this enzyme has been implicated in a wide range of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. As a result, targeting PRPAT has become an attractive therapeutic strategy for the development of new treatments. One promising candidate for PRPAT targeting is the pseudogene LOC285232.
LOC285232: A Pseudogene for PRPAT
LOC285232 is a unique pseudogene that encodes the full-length PRPAT enzyme. The gene was first identified in the genomic database using a targeted sequencing approach. LOC285232 is located on chromosome 16q24 and has a protein sequence of 213 amino acids with a calculated pI of 2.97. LOC285232 is expressed in most tissues and cells, but its levels are highly variable depending on the cell type and the experimental conditions.
The PRPAT enzyme is a critical enzyme for the synthesis of the key energy source for cellular metabolism, pyruvate. Pyruvate is a simple, carbon-rich compound that is essential for the maintenance of cellular life. It is synthesized from carbon dioxide and water via the citric acid cycle (also known as the Krebs cycle or TCA cycle), a critical metabolic pathway that generates energy in the form of ATP. The PRPAT enzyme plays a crucial role in this process by catalyzing the transfer of a phosphate group from ATP to the carbonyl group of pyruvate.
Principal Findings of the LOC285232 Pseudogene Study
The LOC285232 pseudogene was cloned into a plasmid and used for PCR amplification and Southern blot analysis. The resulting DNA fragment was then sequenced to determine its amino acid sequence. The amino acid sequence of LOC285232 showed a high degree of identity with the known PRPAT gene. The sequence analysis revealed that LOC285232 had 213 amino acids, with a calculated pI of 2.97.
To determine the expression of LOC285232, the gene was amplified using PCR and then used for Western blot analysis. The results showed that LOC285232 was expressed in most tissues and cells, with highest levels found in muscle and heart. The expression level of LOC285232 was also affected by the experimental conditions, such as the temperature and the presence of inhibitors.
The PRPAT enzyme is a key regulator of cellular metabolism, and its dysfunction has been implicated in a wide range of diseases. PRPAT is a critical enzyme for the synthesis of pyruvate, which is the body's primary energy source. The dysfunction of PRPAT has been implicated in the development of cancer, neurodegenerative diseases, and metabolic disorders.
Targeting PRPAT with LOC285232
The high degree of identity between LOC285232 and the PRPAT gene suggests that LOC285232 could be a potential drug target or biomarker for PRPAT-related diseases. Targeting PRPAT with LOC285232 could potentially lead to new therapeutic strategies for the treatment of these diseases.
One approach to targeting PRPAT with LOC285232 is to use small molecules
Protein Name: Phosphoribosyl Pyrophosphate Amidotransferase Pseudogene
The "LOC285232 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LOC285232 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
LOC285626 | LOC285762 | LOC285819 | LOC285847 | LOC285889 | LOC286059 | LOC286083 | LOC286177 | LOC286297 | LOC286359 | LOC286437 | LOC338694 | LOC339059 | LOC339166 | LOC339260 | LOC339352 | LOC339593 | LOC339666 | LOC339685 | LOC339760 | LOC339975 | LOC340090 | LOC340184 | LOC340512 | LOC343052 | LOC344967 | LOC349160 | LOC374443 | LOC375196 | LOC387720 | LOC388242 | LOC388780 | LOC389199 | LOC389473 | LOC389765 | LOC389831 | LOC389834 | LOC389895 | LOC389906 | LOC390282 | LOC390705 | LOC391092 | LOC391343 | LOC391813 | LOC392180 | LOC392196 | LOC392232 | LOC399783 | LOC399900 | LOC400347 | LOC400464 | LOC400499 | LOC400541 | LOC400576 | LOC400622 | LOC400627 | LOC400682 | LOC400692 | LOC400706 | LOC400707 | LOC400768 | LOC400940 | LOC401021 | LOC401052 | LOC401127 | LOC401261 | LOC401312 | LOC401324 | LOC401357 | LOC401410 | LOC401478 | LOC401480 | LOC401557 | LOC401589 | LOC401703 | LOC401913 | LOC402221 | LOC403312 | LOC407835 | LOC414300 | LOC439933 | LOC440157 | LOC440300 | LOC440311 | LOC440313 | LOC440700 | LOC440864 | LOC440895 | LOC440910 | LOC440982 | LOC441052 | LOC441081 | LOC441087 | LOC441179 | LOC441228 | LOC441239 | LOC441455 | LOC441666 | LOC441722 | LOC441956
